Schrodinger is a software company that has developed a way to predict how molecules interact with each other down at the molecule to molecule scale using physics and X-ray crystallography. And what this does for drug companies, drug discovery companies, is cut down several years out of the decades long process of finding a drug. They have nine different drugs in their collaboration program in clinical trials, three of which are in phase two and the other six are in phase one. The share price was as high as 110 shortly after they became public but it's since fallen down into the mid-20s.
Regulators seized another bank over the weekend, as the federal government came up with a plan to use money from a fund paid into by U.S. banks to make SVB's depositors whole again.
(0:21) Jason Moser discusses: - Signature Bank failing and shares of First Republic Bank falling 60%. - Why "bailout" is probably not the right word to describe what's happening - How big banks like JPMorgan Chase and Bank of America are gaining strength simply by going about their business
(11:20) We're celebrating our own version of "March Madness" by having analysts face off, bracket-style, as they go head-to-head over which stock is a better buy. Jim Gillies and Jim Mueller kick off the week with a biotech software company and a well-known real estate broker.
Companies discussed: SIVB, SBNY, FRC, SCHW, BAC, JPM, SDGR, RMAX
Host: Chris Hill Guests: Jason Moser, Jim Gillies, Jim Mueller Producer: Ricky Mulvey Engineers: Dan Boyd, Kyle Carruthers
Learn more about your ad choices. Visit megaphone.fm/adchoices